Holen Sie sich die Stockscreener-App
44.80
0.24%
-0.11
Vorhandelsmarkt:
44.80
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TVTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$44.91
Offen:
$45.74
24-Stunden-Volumen:
3.31M
Relative Volume:
1.79
Marktkapitalisierung:
$4.17B
Einnahmen:
$490.73M
Nettoeinkommen (Verlust:
$-50.26M
KGV:
-74.30
EPS:
-0.603
Netto-Cashflow:
$-20.37M
1W Leistung:
+9.56%
1M Leistung:
+47.17%
6M Leistung:
+32.86%
1J Leistung:
+109.25%
1-Tages-Spanne:
$43.06
$48.61
1-Wochen-Bereich:
$39.75
$48.61
52-Wochen-Spanne:
$13.88
$48.61
Travere Therapeutics Inc Stock (TVTX) Company Profile
Firmenname
Travere Therapeutics Inc
Sektor
Branche
Telefon
888-969-7879
Adresse
3611 VALLEY CENTRE DR, SAN DIEGO
Compare TVTX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
44.80 | 4.17B | 490.73M | -50.26M | -20.37M | -0.603 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-10-31 | Bestätigt | Citigroup | Buy |
| 2025-06-11 | Bestätigt | Citigroup | Buy |
| 2025-06-11 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-01-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-21 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-09-09 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-03-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-12-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-11-20 | Eingeleitet | Citigroup | Neutral |
| 2023-09-22 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-07-21 | Eingeleitet | JP Morgan | Overweight |
| 2023-06-07 | Fortgesetzt | Piper Sandler | Neutral |
| 2023-05-22 | Eingeleitet | TD Cowen | Outperform |
| 2023-05-05 | Hochstufung | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-21 | Hochstufung | Wedbush | Neutral → Outperform |
| 2022-12-14 | Eingeleitet | Stifel | Hold |
| 2022-12-05 | Eingeleitet | Wells Fargo | Overweight |
| 2022-09-21 | Eingeleitet | Bryan Garnier | Sell |
| 2022-07-14 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-03-31 | Eingeleitet | Piper Sandler | Overweight |
| 2022-02-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-26 | Herabstufung | Wedbush | Outperform → Neutral |
Alle ansehen
Travere Therapeutics Inc Aktie (TVTX) Neueste Nachrichten
Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes - BioSpace
Director plans sale of 2,181 shares after RSU vesting (NASDAQ: TVTX) - Stock Titan
Insider sells shares; TVTX (NASDAQ: TVTX) files Form 144 reporting RSU vesting - Stock Titan
Jula Inrig sells 20,000 shares (NASDAQ: TVTX) — Form 144 filing - Stock Titan
Insider sale filing — TVTX (NASDAQ: TVTX) Peter Heerma sold 7,215 shares - Stock Titan
Travere Therapeutics plans $400 million convertible notes offering - Investing.com
Roy Baynes files sale of 4,500 shares (NASDAQ: TVTX) under Rule 144 - Stock Titan
Travere Therapeutics plans $400 million convertible notes offering By Investing.com - Investing.com Australia
Travere Therapeutics plans $400M convertible notes offering - MSN
Travere Therapeutics (NASDAQ: TVTX) seeks $400M convertible notes - Stock Titan
Travere lines up $400M debt sale, aims to repurchase 2029 notes - Stock Titan
Travere Therapeutics Analysts Increase Their Forecasts Following Q1 Earnings - Benzinga
MSN Money - MSN
3 Stocks Estimated To Be Trading Up To 49.9% Below Intrinsic Value - simplywall.st
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q1 2026 Earnings Call Transcript - Insider Monkey
Travere Therapeutics price target raised to $57 from $47 at H.C. Wainwright - TipRanks
Travere Therapeutics, Inc. Q1 2026: Financial Results, Risk Factors, and Management Discussion - Minichart
Travere Therapeutics Reports First Quarter 2026 Financial Results - BioSpace
Travere Therapeutics Inc SEC Filings - Stock Titan
How (TVTX) Movements Inform Risk Allocation Models - Stock Traders Daily
Why Travere Therapeutics (TVTX) Is Up 10.0% After Stronger Q1 2026 Results And Narrower Loss - simplywall.st
Travere Therapeutics Bets Big on FILSPARI Momentum - TipRanks
Travere Therapeutics : Investor Fact Sheet - marketscreener.com
Travere Therapeutics, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Travere Therapeutics Q1 Earnings Call Highlights - Yahoo Finance
TVTX: FILSPARI's FDA approval in FSGS fueled record Q1 sales and positions for rapid future growth - TradingView
Travere Therapeutics (TVTX) reports Q1 loss, misses revenue estimates - MSN
TVTX: Record Filspari sales and first FSGS approval drive strong growth and outlook - TradingView
Travere (TVTX) Q1 2026 Earnings Transcript - The Globe and Mail
Earnings call transcript: Travere Q1 2026 sees mixed results, stock rises - Investing.com Australia
Travere Therapeutics reports Q1 EPS 5c, consensus (5c) - TipRanks
Compared to Estimates, Travere (TVTX) Q1 Earnings: A Look at Key Metrics - Yahoo Finance Singapore
Travere Therapeutics Q1 Swings to Profit, Revenue Rises - marketscreener.com
Travere Therapeutics : Q1 2026 Earnings Presentation - marketscreener.com
Travere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Travere therapeutics director Roy Baynes sells $431,145 in stock. By Investing.com - Investing.com Canada
Travere Therapeutics (NASDAQ: TVTX) grows FILSPARI sales as FDA fully approves FSGS use - Stock Titan
Travere therapeutics director Roy Baynes sells $431,145 in stock. - Investing.com
Travere Therapeutics 1Q 2026: Revenue $127.2M, EPS ($0.4) — 10-Q Summary - TradingView
TVTX: FILSPARI sales drove 56% revenue growth and improved net loss, with strong liquidity maintained - TradingView
Travere Therapeutics falls on revenue miss despite record demand By Investing.com - Investing.com Australia
Travere Therapeutics falls on revenue miss despite record demand - Investing.com
Q1 2026 Travere Therapeutics Inc Earnings Call Transcript - GuruFocus
Earnings Flash (TVTX) Travere Therapeutics, Inc. Posts Q1 Adjusted EPS $0.05 per Share - marketscreener.com
Travere Therapeutics (TVTX) director sells 9,750 shares via 10b5-1 plan - Stock Titan
Earnings Flash (TVTX) Travere Therapeutics, Inc. Reports Q1 Revenue $127.2M, vs. FactSet Est of $136.2M - marketscreener.com
Travere: Q1 Earnings Snapshot - wwltv.com
FILSPARI growth lifts Travere (NASDAQ: TVTX) to Q1 2026 non-GAAP profit - Stock Titan
20,000-share sale notice for Morgan Stanley Smith Barney (TVTX) via option exercise - Stock Titan
[144] Travere Therapeutics, Inc. SEC Filing - Stock Titan
TVTX (NASDAQ) files Rule 144 for 20,000-share option exercise; prior April sales listed - Stock Titan
Finanzdaten der Travere Therapeutics Inc-Aktie (TVTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):